Rein Therapeutics RNTX
NASDAQ RNTX
$0.80 -0.05 (-5.88%)
At close: Oct 2, 2026 · 4:00 PM EDT

Rein Therapeutics (RNTX) Other Accumulated Expenses (2018)

Updated

Rein Therapeutics (RNTX) reported Other Accumulated Expenses of $3.64 million for Q4 2018.

Analysis

Rein Therapeutics (RNTX) Other Accumulated Expenses (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Rein Therapeutics 53.67 Mn 53.67 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 3.64 Mn
API Access

Rein Therapeutics Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=RNTX&period=max&api_key=YOUR_API_KEY